Denervation is a hallmark of age-related and other types of muscle wasting. This review focuses on recent insights and current viewpoints regarding the mechanisms and clinical relevance of maintaining the neuromuscular junction to counteract muscle wasting resulting from aging or neural disease/damage.
INTRODUCTION
Sedentary lifestyle and aging make muscle wasting an increasing health burden. Being at the crossroad between nerve and muscle [1] , neuromuscular junctions are entering center stage for basic concepts, diagnosis, and therapy of muscle wasting [2 && ]. Recent progress in the understanding of neuromuscular junction functions in muscle wasting and their application to clinical aspects are reviewed here.
MUSCLE WASTING, THE ATROGENE CONCEPT, AND NEUROMUSCULAR JUNCTION
Several conditions including aging, disuse, heart failure, diabetes, cancer, and neuromuscular transmission disorders lead to profound muscle wasting and weakness. A common set of proteins are strongly up or down-regulated under different conditions leading to muscle wasting (also called muscle atrophy) and were termed 'atrogenes' [3] . Two of these proteins, namely Atrogin-1 and MuRF1, are E3 ubiquitin ligases and have been characterized as the key regulators for the proteasomal degradation of muscle tissue under muscle wasting conditions. The finding that the neuromuscular junction fragments and loses functionality upon aging-related muscle wasting (sarcopenia) and other atrophic conditions, and that these phenomena are partially reversible by metabolic maneuvers [4] [5] [6] [7] [8] have spurred interest in understanding the molecular links between muscle wasting and related neuromuscular junction phenotypes. Notably, although MuRF1 was generally considered to orchestrate sarcomeric protein degradation upon muscle wasting, it was recently found to be clearly enriched at the neuromuscular junction and to be involved in muscle wastinginduced autophagic degradation of a major neuromuscular junction component, that is, nicotinic acetylcholine receptor (AChR) [9, 10] . These studies linked the atrogene concept to neuromuscular junction maintenance and autophagy. Increased turnover of AChR, fragmentation of neuromuscular junctions, and precocious synaptic dysfunction including partial denervation were observed in mice with skeletal muscle-specific loss of autophagyrelated protein 7, a principal component of the autophagy machinery [11 & ]. This further supported a major role of autophagy for neuromuscular junction homeostasis. Accordingly, autophagy was found to be dysregulated in skeletal muscle of aging dogs [12] and humans [11 & ]. It has been determined that caloric restriction and physical exercise are beneficial for rescuing neuromuscular junction fragmentation [2 && ,13,8] and innervation status [2 && ,14] , and at the same time reduce impairment of autophagy [11 & ] as well as sarcopenia onset or progression [15] [16] [17] [18] . This suggests autophagy modulation to be a potential therapeutic target in neuromuscular transmission disorders ( Fig. 1 ).
AGRIN SIGNALING -DIAGNOSTIC AND THERAPEUTIC TOOLBOX FOR MUSCLE WASTING
Although autophagy and other vesicular trafficking processes are key to the delivery, distribution, and degradation of neuromuscular junction components, the agrin-muscle specific kinase (MuSK)-Lrp4 signaling axis mediates crosstalk between nerve and muscle [2 && ] ( Fig. 1 ). Indeed, neuronal agrin is released by the motor neuron into the synaptic cleft where it binds to the Lrp4 coreceptor to activate the receptor tyrosine kinase MuSK. This leads to stabilization and clustering of AChR via Dok-7 and further mechanisms that involve also the 43 kDa-protein rapsyn. The agrin-MuSK-Lrp4
KEY POINTS
Degeneration of neuromuscular junction is important in the context of some types of muscle wasting, particularly those resulting from aging or neural damage/disease. Degeneration of neuromuscular junctions is modulated by autophagy, the agrin-MuSK-Lrp4 and Wnt signaling axis, and sympathetic input.
C-terminal fragment of agrin is being evaluated as biomarker for muscle wasting.
Modulation of autophagy, agrin fragments, modulation of Dok-7 expression, and sympathicomimetics are being investigated for their therapeutic function in neuromuscular junctionrelated muscle wasting. . Also, neuromuscular junction remodeling that entails reorganization of AChR patches for maintaining a tight presynaptic-to-postsynaptic matching appears to require local cleavage of agrin. This is executed by the protease neurotrypsin and leaves a C-terminal agrin fragment (CAF, Fig. 1 ), which becomes soluble and circulates in the blood. Given massive neuromuscular junction remodeling in the course of some forms of muscle wasting and particularly during sarcopenia, the use of circulating CAF levels as a diagnostic tool of neuromuscular junction disintegration has become an attractive concept [20] . Indeed, recent clinical investigations supported the efficacy of CAF as a biomarker for sarcopenia primarily in men [21] [22] [23] . However, sample sizes in these studies are still small asking for larger trials.
Apart from the diagnostic relevance of CAF, a neurotrypsin-resistant and soluble NT-1654 fragment of agrin ( Fig. 1 ) was tested with respect to its therapeutic efficacy [24] . Subcutaneous injection of the compound into neurotrypsin-overexpressing mice largely rescued their sarcopenic phenotype, which includes severe precocious muscle wasting, weakness, and neuromuscular junction degeneration. Another study investigated the therapeutic efficacy of modulating Dok-7 abundance and revealed that adeno-associated virus-mediated gene therapy to overexpress Dok-7 was able to significantly reduce the symptoms of two different CMS models, including a prolongation of life span in an Emery-Drifuss CMS model and a complete rescue in Dok-7 knockout mice [25] . Although the therapeutic activity of both the NT-1654 agrin fragment as well as the Dok-7 have been explored only in rodents so far, these studies suggest that neuromuscular junction-related muscle wasting might in the future be amenable for pharmacological intervention.
LRP4 AND SLIT2 -BIDIRECTIONAL COMMUNICATION AT THE NERVE-MUSCLE INTERFACE
As mentioned before, Lrp4 is a major mediator of postsynaptic stability at the neuromuscular junction [2 && ] and its persistent activity is necessary to maintain synaptic integrity and function throughout adulthood as shown by inducible Lrp4 knockout mice [26] . Although Lrp4 is now an established causative gene for some forms of CMS [27, 28] it has recently also been implicated in the pathogenesis of a motor neuron disease, namely amyotrophic lateral sclerosis (ALS). Indeed, Lrp4 autoantibodies were found in a high proportion of ALS patients, while they were absent in other neurological disorders [29] . Some studies now consider ALS, which is characterized by late onset and fast progression, as a disease that originates at the neuromuscular junction followed by progressive 'dyingback' of the rest of the neuron. Indeed, alterations of synaptic function [30] of the presynaptic terminal [31], and of terminal Schwann cells [32] , which shield the neuromuscular junction, were found to precede symptom onset in mouse models of ALS and Charcot-Marie-Tooth disease. As recently reviewed, Lrp4 may act as a retrograde signal orchestrating presynaptic organization at the neuromuscular junction ]. Furthermore, these data highlight a well established [2 && ] but complex role [35, 36] of Wnt signaling in neuromuscular junction formation and maintenance as well as after traumatic injury [37] . The earlier mentioned screen of aging-related alterations of gene expression in humans [34 morphology and function, leading to muscle wasting and weakness. In clinical practice, many CMS patients have been found to respond well to treatment with b-adrenergic agonists, such as albuterol, salbutamol, or ephedrine [19 & ,27,28,39] (Fig. 1) . Fittingly, neuromuscular junctions have been recently identified as target of direct sympathetic innervation and this appears to be crucial for the homeostasis of neuromuscular junctions, for example by modulating AChR expression [40 && ]. The mechanisms underlying the therapeutic efficacy of b-adrenergic agonists are likely pleiotropic in nature and might involve enhancement of gene expression [40 && ], protein metabolism, inhibition of proteolysis, improvement of mitochondrial function, effects on the release of trophic factors, and the modulation of immune cells [41] .
CONCLUSION
Several forms of muscle wasting, including sarcopenia, have an important denervation component. Although muscle wasting can be observed also in the absence of neuromuscular junction derangements [42] , strong links between neuromuscular junction impairment and repair of muscle wasting in particular upon aging and neural damage have been observed. Accordingly, measures to maintain and enforce neuromuscular junctions are increasingly becoming a focus in clinical research. The study uses several elegant genetic models to demonstrate the role of Slit2 in mediating retrograde signaling from post-to-presnapse at the neuromuscular junction. 34.
